Literature DB >> 11069582

Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor.

D Kirik1, C Rosenblad, A Björklund.   

Abstract

Here we studied whether glial cell line-derived neurotrophic factor (GDNF), given as a single bolus injection before an intrastriatal 6-hydroxydopamine (6-OHDA) lesion, can protect the nigrostriatal dopamine neurons against the toxin-induced damage and preserve normal motor functions in the lesioned animals. GDNF or vehicle was injected in the striatum (25 microg), substantia nigra (25 microg) or lateral ventricle (50 microg) 6 h before the 6-OHDA lesion (20 microg/3 microL). Motor function was evaluated by the stepping and drug-induced motor asymmetry tests. Lesioned animals given vehicle alone showed a clear ipsilateral-side bias in response to amphetamine (13 turns/min), a moderate contralateral-side bias to apomorphine (4.5 turns/min) and a moderate to severe stepping deficit on the contralateral forepaw (three to four steps, as compared with 11-13 steps on the unimpaired side). Injection of GDNF into the striatum had a significant protective effect both on nigrostriatal function (1-2 turns/min in the rotation tests and seven to eight steps in the stepping test), and the integrity of the nigrostriatal pathway, seen as a protection of both the cell bodies in the substantia nigra and the dopamine innervation in the striatum. Injection of GDNF in the nigra had a protective effect on the nigral cell bodies, but not the striatal innervation, and failed to provide any functional benefit. In contrast, intranigral GDNF had deleterious effects on both the striatal TH-positive fibre density and on drug-induced rotation tests. Intraventricular injection had no effect. We conclude that preservation of normal motor functions in the intrastriatal 6-OHDA lesion model requires protection of striatal terminal innervation, and that this can be achieved by intrastriatal, but not nigral or intraventricular, administration of GDNF.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11069582     DOI: 10.1046/j.1460-9568.2000.00274.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  39 in total

Review 1.  Parkinson's disease: gene therapies.

Authors:  Philippe G Coune; Bernard L Schneider; Patrick Aebischer
Journal:  Cold Spring Harb Perspect Med       Date:  2012-04       Impact factor: 6.915

2.  Striatal readministration of rAAV vectors reveals an immune response against AAV2 capsids that can be circumvented.

Authors:  Carmen S Peden; Fredric P Manfredsson; Sharon K Reimsnider; Amy E Poirier; Corinna Burger; Nicholas Muzyczka; Ronald J Mandel
Journal:  Mol Ther       Date:  2009-01-13       Impact factor: 11.454

Review 3.  Glial-derived neurotrophic factor gene transfer for Parkinson's disease: anterograde distribution of AAV2 vectors in the primate brain.

Authors:  Adrian P Kells; John Forsayeth; Krystof S Bankiewicz
Journal:  Neurobiol Dis       Date:  2011-10-14       Impact factor: 5.996

Review 4.  Trophic factors therapy in Parkinson's disease.

Authors:  Shilpa Ramaswamy; Katherine E Soderstrom; Jeffrey H Kordower
Journal:  Prog Brain Res       Date:  2009       Impact factor: 2.453

5.  Transgenic expression of human glial cell line-derived neurotrophic factor from integration-deficient lentiviral vectors is neuroprotective in a rodent model of Parkinson's disease.

Authors:  Ngoc B Lu-Nguyen; Martin Broadstock; Maximilian G Schliesser; Cynthia C Bartholomae; Christof von Kalle; Manfred Schmidt; Rafael J Yáñez-Muñoz
Journal:  Hum Gene Ther       Date:  2014-04-15       Impact factor: 5.695

6.  Nanodelivery of Cerebrolysin and Rearing in Enriched Environment Induce Neuroprotective Effects in a Preclinical Rat Model of Parkinson's Disease.

Authors:  C Requejo; J A Ruiz-Ortega; H Cepeda; A Sharma; H S Sharma; A Ozkizilcik; R Tian; H Moessler; L Ugedo; J V Lafuente
Journal:  Mol Neurobiol       Date:  2018-01       Impact factor: 5.590

7.  Long-term restoration of nigrostriatal system function by implanting GDNF genetically modified fibroblasts in a rat model of Parkinson's disease.

Authors:  Deyi Duan; Hui Yang; Jingzhong Zhang; Jinlu Zhang; Qunyuan Xu
Journal:  Exp Brain Res       Date:  2004-10-12       Impact factor: 1.972

8.  Neuroprotective potential of pleiotrophin overexpression in the striatonigral pathway compared with overexpression in both the striatonigral and nigrostriatal pathways.

Authors:  S E Gombash; F P Manfredsson; R J Mandel; T J Collier; D L Fischer; C J Kemp; N M Kuhn; S L Wohlgenant; S M Fleming; C E Sortwell
Journal:  Gene Ther       Date:  2014-05-08       Impact factor: 5.250

9.  Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease.

Authors:  X Yue; D J Hariri; B Caballero; S Zhang; M J Bartlett; O Kaut; D W Mount; U Wüllner; S J Sherman; T Falk
Journal:  Neuroscience       Date:  2013-11-27       Impact factor: 3.590

10.  Overexpression of glial cell line-derived neurotrophic factor using a lentiviral vector induces time- and dose-dependent downregulation of tyrosine hydroxylase in the intact nigrostriatal dopamine system.

Authors:  Biljana Georgievska; Deniz Kirik; Anders Björklund
Journal:  J Neurosci       Date:  2004-07-21       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.